Translational research such as that proposed in the Melanoma and Skin Program (MSCP) SPORE has a spectrum of needs that benefit from software solutions, including clinical information annotation, data warehousing and disease modeling/analysis tools. The informatics Core (Core D) will serve the Projects and Cores of the MSCP SPORE in the following ways: Project 1. The Informatics Core will be responsible for the data extraction and clinical annotations by the Research Information Service (RIS) to support the El609 patient cohort and ensure the integration of these data into the Research Data Warehouse (RDW) for use by Biostatistics Core (Core C). Project 2. The Informatics Core will assist in studying the management of the toxicities associated with the treatment in the Project 2 cohorts using our clinical phenotyping tool. This project also requires use the Core D's Clinical Trials Management Application (CTMA) and our clinical annotation expertise provided by the RIS. Of note, CTMA will serve all of the Projects'Clinical Research Management System (CRMS) needs. Project 3. Core D will provide access to the clinical annotation data for Project 3 and make these data available to the SPORE team as well as the Biostatistics Core. The study will collect data electronically from our Electronic Medical Record (EMR) systems and analyze it with our cohort discovery tool (GIANT). The research data generated from this project will also be incorporated into our RDW. Project 4. Core D will develop algorithms (via GIANT) to identify patients with in transit melanoma that may be eligible for inclusion in this project and coordinate the collection of clinical annotations from RIS. Core A (Administrative). The Informatics Core will ensure requisite trial data are recorded, stored, backed up, and available for review and annual reporting by the Project PIs to the Internal and External Advisory Boards and the National Cancer Institute. In addition, the Informatics Core will be responsible for all network storage and data sharing within the MSCP SPORE and for Intra-SPORE collaborations and will support the Developmental Research and Career Development Projects managed in Core A.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
United States
Zip Code
Dulmage, B O; Feng, H; Mirvish, E et al. (2015) Black cat in a dark room: the absence of a directly oncogenic virus does not eliminate the role of an infectious agent in cutaneous T-cell lymphoma pathogenesis. Br J Dermatol 172:1449-51
Sabbatino, Francesco; Wang, Yangyang; Wang, Xinhui et al. (2014) PDGFR? up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget 5:1926-41
Tarhini, Ahmad A; Edington, Howard; Butterfield, Lisa H et al. (2014) Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One 9:e87705
Ng, Yuen-Keng; Lee, Jia-Ying; Supko, Kathryn M et al. (2014) Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Melanoma Res 24:207-18
Tarhini, Ahmad A; Shin, Donghoon; Lee, Sandra J et al. (2014) Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa. Melanoma Res 24:150-7
Pancoska, Petr; Kirkwood, John M; Bouros, Spyros et al. (2014) A new mathematical model for the interpretation of translational research evaluating six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon. PLoS One 9:e86375
Tarhini, Ahmad A; Lin, Yan; Yeku, Oladapo et al. (2014) A four-marker signature of TNF-RII, TGF-?, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. J Transl Med 12:19
Geskin, Larisa J; Akilov, Oleg E; Lin, Yan et al. (2014) Distinct age-matched serum biomarker profiles in patients with cutaneous T-cell lymphoma. Exp Dermatol 23:598-600
Schowalter, Michael K; Dulmage, Brittany O; Ho, Jonhan et al. (2014) Comparative proteomic analysis reveals unique tumor protein composition among the melanoma subtypes pure desmoplastic and superficial spreading. Melanoma Res 24:397-400
McArthur, Grant A; Chapman, Paul B; Robert, Caroline et al. (2014) Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15:323-32

Showing the most recent 10 out of 59 publications